ProMIS Neurosciences, Inc. (PMN) Amount of Cash per Share

The lack of recurring revenue makes the stability of ProMIS Neurosciences (PMN) dependent on the outcome of drug trials. Current cash per share confirms liquidity, with the metric holding around 4.87. The development of selective amyloid antibodies to combat Alzheimer's disease, as well as the potential for acquisition by pharmaceutical market behemoths following successful clinical phases, mitigates these risks.
Analytical breakdowns for ProMIS Neurosciences

Geopolitical instability and sanctions are complicating the funding of neurological research at ProMIS Neurosciences (PMN). The dynamics of free cash flow per share allow for a real-time assessment of the company's current liquidity against these risks. The 4.87 metric is calculated by dividing the total amount of highly liquid assets by the total number of shares. This metric determines the balance sheet's margin of safety for covering operating expenses. An increase in this value confirms financial autonomy, reducing the business's reliance on external borrowing.